
    
      A randomized, single-dose, parallel group, comparative PK study. Patients will be randomly
      assigned in 1:1 ratio to the study products. Twenty four (24) consenting patients, age 18
      years and older, who meet Inclusion/Exclusion criteria will be enrolled in this study. 12
      Patients will be treated with Malathion Gel, 0.5% and other 12 Patients will be treated with
      Ovide Lotion 0.5%. The study will be single centre and conducted only in India. The primary
      objective of this study is to compare the systemic exposure of Malathion 0.5% Gel
      manufactured by Taro Pharmaceuticals USA, Inc. to that of the OVIDE Lotion 0.5%, currently
      marketed by Taro Pharmaceutical USA, Inc., in adult Patients with head lice. The secondary
      objective is to determine the link between the exposure and cholinesterase activity.
    
  